Strategic Partnerships Destiny Pharma has actively engaged in collaborations with pharmaceutical companies such as Sebela Pharmaceuticals and China Medical Systems, presenting opportunities to provide advanced formulation development, licensing support, or co-marketing services to enhance their product pipelines.

Clinical Asset Development With promising clinical-stage assets like NTCD-M3 and XF-73, the company may benefit from solutions that support clinical trial management, regulatory consultancy, or drug delivery innovations to accelerate their development timelines.

Financial Challenges Recent administrative appointments due to capital access issues suggest opportunities to offer funding solutions, investment partnerships, or financial advisory services to help stabilize and grow the company's pipeline.

Emerging Market Focus Destiny Pharma’s partnerships in China and focus on novel biotherapeutics indicate potential sales channels in international markets for distribution, licensing, or technology transfer to expand their global footprint.

Innovative Technology Use The company's focus on microbiome-based therapeutics and biotherapeutics opens avenues for offering cutting-edge biotech tools, lab automation, or research collaborations that can enhance their R&D capabilities.